Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT04423380 Recruiting - Clinical trials for Advanced Solid Tumor

A Study to Investigate Safety and Tolerability of SH3051 Capsule in Patients With Advanced Solid Tumors

Start date: May 14, 2020
Phase: Phase 1
Study type: Interventional

The primary objective is to determine the safety profile of SH3051 in subjects with advanced solid tumors. The second objective is to evaluate the PK profile and preliminary efficacy of SH3051 solid tumors.

NCT ID: NCT04423185 Not yet recruiting - Rare Tumor Clinical Trials

PLATFORM Study of Precision Medicine for Rare Tumors

Start date: August 15, 2020
Phase: Phase 2
Study type: Interventional

A Phase II, open label, non-randomized, multiple-arm, single-center clinical trial in patients with advanced rare solid tumors who failed to standard treatment.

NCT ID: NCT04420689 Completed - Surgery Clinical Trials

A Study of ALM-488 to Highlight Nerves in Patients Undergoing Head & Neck Surgery

Start date: June 18, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

Phase 1/2 study of ALM-488 to highlight nerves in patients undergoing head & neck surgery.

NCT ID: NCT04419532 Recruiting - Solid Tumor Clinical Trials

A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors

Start date: October 9, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety and tolerability of DS-1055a in participants with relapsed or refractory locally advanced or metastatic solid tumors for which no standard treatment is available.

NCT ID: NCT04418167 Suspended - Solid Tumors Clinical Trials

JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

Start date: June 18, 2020
Phase: Phase 1
Study type: Interventional

This is a Phase 1 study of JSI-1187 as monotherapy and in combination with dabrafenib for the treatment of advanced solid tumors with MAPK pathway mutations, including mutations that cause MAPK pathway hyperactivation.

NCT ID: NCT04416685 Completed - Clinical trials for Pancreatic Neoplasm Malignant Head Primary

A New Anatomical Classification of Portal Vein Location of Pancreas Tumors

Start date: May 1, 2014
Phase: N/A
Study type: Interventional

In this retrospective study, we recorded the location of pancreatic tumors and relation/proximity to the portal vein. The surgical difficulty and requirement of additional interventions were also evaluated.

NCT ID: NCT04416672 Recruiting - Malignant Neoplasms Clinical Trials

Validation of the Italian Version of the PRO-CTCAE

Start date: July 1, 2018
Phase:
Study type: Observational

The aim of this study is to complete the validation process by testing the remaining two psychometric properties (validity and responsiveness) of the Italian version of the PRO-CTCAE in a large group of patients. In particular, for the first time this study will validate the tool for individual types of cancer and will provide information on psychometric properties based on the type of treatment used in clinical practice.

NCT ID: NCT04416568 Recruiting - Epithelioid Sarcoma Clinical Trials

Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers

Start date: August 14, 2020
Phase: Phase 2
Study type: Interventional

This clinical trial is studying two immunotherapy drugs (nivolumab and ipilimumab) given together as a possible treatment for INI1-negative tumors.

NCT ID: NCT04414150 Completed - Malignant Tumours Clinical Trials

A Trial of SHR-1802 in Patients With Failure of Standard Treatment for Advanced Malignant Tumours

Start date: June 17, 2020
Phase: Phase 1
Study type: Interventional

This is the first study to test SHR-1802 in humans. The primary purpose of this study is to see if SHR-1802 is safe and tolerable for patients with locally advanced/unresectable or metastatic malignancies that are refractory to available therapy or for which no standard therapy is available.

NCT ID: NCT04413227 Recruiting - Solid Tumor Clinical Trials

A Phase Ib Study With Pegylated Recombinant Human Endostatin in Advanced / Metastatic NSCLC or Other Solid Tumors

Start date: April 2, 2020
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to examine the safety, tolerability and pharmacokinetics of PEG-ENDO in combination with docetaxel in subjects previously treated or untreated (standard therapy is not suitable or without standard therapy) for advanced or metatatic non-small cell lung cancer (NSCLC) or other solid tumors.